December 19, 2018 - Scientists at the KU Leuven Rega Institute, members of both the ZikaPLAN and ZIKAlliance consortia, have developed a new vaccine against the Zika virus. This vaccine should prevent the virus from causing microcephaly and other serious ... Read more
November 29, 2018 - Diagnosing Zika in the field presents specific challenges as other diseases, such as chikungunya and dengue, present in the same areas, can give a false positive on diagnostic tests. Read more
November 23, 2018 - The mosquito Aedes aegypti should be considered one of the most dangerous animals on the planet. This is because the Aedes aegypti female carries several viruses that can cause diseases such as yellow fever, dengue and ... Read more
September 19, 2018 - On the 11 and 12of September, scientists from leading research organizations across the world met for the ZikaPLAN Consortium meeting at the London School of Hygiene & Tropical Medicine in the UK. Read more
July 9, 2018 - ZikaPLAN’s NEURO-ZIKA neurological manifestations working group leader, the University of Liverpool, has been working with another working group member, Fiocruz, and the Brazilian Ministry of Health, the Brazilian charities ‘Uniao de Maes dos Anjos-UMA’ (Recife), ‘Associação ... Read more
Tricot et al. - PLOS ONE, December 19, 2018
High levels of ZIKV RNA have been detected in mice and non-human primates in organs other than the brain, such as the liver, and closely related flaviviruses, the dengue and yellow fever viruses, are known to cause hepatitis. This study examines ZIKV infection of human hepatocytes.
Defining the spectrum of neurological diseases associated with Zika virus (ZIKV) infection, in both the central nervous system (CNS) and peripheral nervous system (PNS) of adults and children.
To protect pregnant women, novel, wash-in detergent formulations and long-lasting plastic technologies containing repellents for the treatment of clothing and other wearable repellent technologies are being developed using new microencapsulation techniques.
Identifying the major T-cell epitopes and cross reactive B-cell epitopes on ZIKV and assessing the role of flavivirus antibodies in protective and pathogenic immunity following ZIKV through antibody dependent enhancement (ADE).
ZikaPLAN has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 734584.